Afficher la notice abrégée

Risk of severe clinical events after sustained virological response following direct-acting antiviral therapy in HIV and hepatitis C virus coinfected participants

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorCHALOUNI, Mathieu
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorWITTKOP, Linda
dc.contributor.authorBANI-SADR, Firouze
dc.contributor.authorLACOMBE, Karine
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorESTERLE, Laure
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorGILBERT, Camille
dc.contributor.authorMIAILHES, Patrick
dc.contributor.authorZUCMAN, David
dc.contributor.authorVALANTIN, Marc Antoine
dc.contributor.authorBREGIGEON-RONOT, Sylvie
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMORLAT, Philippe
dc.contributor.authorBILLAUD, Eric
dc.contributor.authorPIROTH, Lionel
dc.contributor.authorNAQVI, Alissa
dc.contributor.authorSOGNI, Philippe
dc.contributor.authorSALMON, Dominique
dc.contributor.authorGROUP, Anrs Co Hepavih Cohort Study
dc.date.accessioned2021-08-27T08:47:27Z
dc.date.available2021-08-27T08:47:27Z
dc.date.issued2021-07-01
dc.identifier.issn1464-2662en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/110228
dc.description.abstractEnOBJECTIVES: Sustained virological response (SVR) decreases the risk of hepatitis C virus (HCV)-related events. Nevertheless, a substantial risk of events persists. We estimated incidences and identified factors associated with severe clinical events after SVR following treatment with a direct-acting antiviral (DAA) in HIV/HCV-coinfected patients. METHODS: Participants from the ANRS CO13 HEPAVIH were included if they reached SVR. Incidence rates of overall mortality, liver-related events, AIDS-defining events, ischaemic events and non-liver non-AIDS-defining cancers (NLNA) were estimated. Factors associated with the risk of those events were identified using Poisson models adjusted on age at SVR and sex. RESULTS: In all, 775 participants were included. Incidence rates (95% confidence interval) of liver-related events, overall mortality, AIDS-defining events, ischaemic events and NLNA cancers per 1000 person-years were 5.9 (3.3-10.3), 22.2 (16.8-29.5), 0.6 (0.1-4.5), 7.3 (4.4-12.2) and 13.7 (9.4-20.0), respectively. For all events, incidence rates were higher in cirrhotic than in non-cirrhotic participants. Cirrhosis, liver stiffness and CD4 count were associated with liver-related events. Factors associated with overall mortality were age, cirrhosis, liver stiffness and gamma-glutamyl transferase (GGT). For ischaemic events and NLNA cancers, associated factors were total cholesterol and CD4 count, respectively. CONCLUSIONS: After SVR following a DAA treatment, liver-related and AIDS-defining events were observed less frequently than NLNA cancers. Severity of liver disease was associated with the risk of liver-related events and of overall mortality but not with ischaemic events and NLNA cancers. Factors reflecting HIV infection were associated with NLNA cancers and liver-related events.
dc.language.isoENen_US
dc.subject.enDAA treatment
dc.subject.enHCV coinfection
dc.subject.enHIV
dc.subject.enMortality
dc.subject.enMorbidity
dc.subject.enSVR
dc.title.enRisk of severe clinical events after sustained virological response following direct-acting antiviral therapy in HIV and hepatitis C virus coinfected participants
dc.typeArticle de revueen_US
dc.identifier.doi10.1111/hiv.13127en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed34212476en_US
bordeaux.journalHIV Medicineen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamANRS CO13 HEPAVIHen_US
bordeaux.teamMORPH3Eusen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03327400
hal.version1
hal.date.transferred2021-08-27T08:47:32Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=HIV%20Medicine&rft.date=2021-07-01&rft.eissn=1464-2662&rft.issn=1464-2662&rft.au=CHALOUNI,%20Mathieu&WITTKOP,%20Linda&BANI-SADR,%20Firouze&LACOMBE,%20Karine&ESTERLE,%20Laure&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée